Biotech stocks make for an interesting study. They represent a high-risk sector, characterized by famously high overhead and long lead times to develop new products. However, they also hold the potential for high rewards when new drugs open up markets with potential sales targets sometimes reaching billions of dollars. It’s not just the future sales potential that fuels the possibilities for rewards; a successful small-cap biotech company, with a newly approved drug, will frequently attract merg